Skip to content

Evaluation of the Effect of rTMS on Attention in Adults Diagnosed With Attention-Deficit Hyperactivity Disorder (ADHD)

Evaluation of the Effect of rTMS on Attention in Adults Diagnosed With ADHD

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00825708
Enrollment
20
Registered
2009-01-21
Start date
2007-03-31
Completion date
Unknown
Last updated
2009-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder

Keywords

ADHD

Brief summary

The aim of the study is to evaluate the immediate effect of rTMS on attention in adults diagnosed with ADHD. the design is a double blind sham controlled crossover study.

Detailed description

The subjects were randomly assigned to two groups. group 1 starts with the real rTMS session followed within one week with a sham session. group 2 starts with a sham session and within one week recieve a real session. the subjects go through a neurocognitive evaluation before and after rTMS sessions and a clinical evaluation questionnaire modified for attention.

Interventions

DEVICErTMS

42 2 sec trains of 20HZ rTMS in 100% MT

DEVICEshamTMS

sham TMS session

Sponsors

Shalvata Mental Health Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* age 18-65 * diagnosis of ADHD according to DSM IV criteria

Exclusion criteria

* other axis I diagnosis * risk factors for seizure

Design outcomes

Primary

MeasureTime frame
PANNAS questionnaire modified for attentionwithin one hour of the rTMS session

Secondary

MeasureTime frame
the CANTAB neurocognitive batterywithin 2 hours of the stimulation

Countries

Israel

Contacts

Primary ContactEiran V Harel, MD
evharel@clalit.org.il097478644

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026